CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia

Khalil Saleh; Florence Pasquier; Camille Bigenwald; Stéphane De Botton; Vincent Ribrag; Cristina Castilla-Llorente

doi:10.3390/jcm12216883

CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia

Khalil Saleh, Florence Pasquier, Camille Bigenwald, Stéphane De Botton, Vincent Ribrag, Cristina Castilla-Llorente

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

Résumé

B-cell acute lymphoblastic leukemia (B-ALL) is the most common subtype of acute leukemia in the pediatric population. The prognosis and treatment of B-ALL have dramatically improved over the past decade with the adoption of intensive and prolonged combination chemotherapy regimens. The advent of novel immunologic agents such as blinatumomab and inotuzumab has changed the treatment landscape of B-ALL. However, patients have continued to relapse, raising the need for novel therapies. Chimeric antigen receptor (CAR) T-cells have achieved a milestone in the treatment of B-ALL. Two CD19-targeting CAR T-cells were approved by the Food and Drug Administration and the European Medicines Agency for the treatment of relapsed and/or refractory B-ALL. In this review, we review the available data regarding CD19-targeting CAR T-cells with their safety profile as well as the mechanism of resistance to these agents and the way to overcome this resistance.

langue originale	Anglais
Numéro d'article	6883
journal	Journal of Clinical Medicine
Volume	12
Numéro de publication	21
Les DOIs	https://doi.org/10.3390/jcm12216883
état	Publié - 1 nov. 2023

Accès au document

10.3390/jcm12216883

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{b4ff03aec5d04459a997a5b2ffc47fa2,

title = "CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia",

abstract = "B-cell acute lymphoblastic leukemia (B-ALL) is the most common subtype of acute leukemia in the pediatric population. The prognosis and treatment of B-ALL have dramatically improved over the past decade with the adoption of intensive and prolonged combination chemotherapy regimens. The advent of novel immunologic agents such as blinatumomab and inotuzumab has changed the treatment landscape of B-ALL. However, patients have continued to relapse, raising the need for novel therapies. Chimeric antigen receptor (CAR) T-cells have achieved a milestone in the treatment of B-ALL. Two CD19-targeting CAR T-cells were approved by the Food and Drug Administration and the European Medicines Agency for the treatment of relapsed and/or refractory B-ALL. In this review, we review the available data regarding CD19-targeting CAR T-cells with their safety profile as well as the mechanism of resistance to these agents and the way to overcome this resistance.",

keywords = "B-cell acute lymphoblastic leukemia, blinatumomab, brexucabtagene autoleucel, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, tisagenlecleucel",

author = "Khalil Saleh and Florence Pasquier and Camille Bigenwald and {De Botton}, St{\'e}phane and Vincent Ribrag and Cristina Castilla-Llorente",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = nov,

day = "1",

doi = "10.3390/jcm12216883",

language = "English",

volume = "12",

journal = "Journal of Clinical Medicine",

issn = "2077-0383",

number = "21",

}

TY - JOUR

T1 - CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia

AU - Saleh, Khalil

AU - Pasquier, Florence

AU - Bigenwald, Camille

AU - De Botton, Stéphane

AU - Ribrag, Vincent

AU - Castilla-Llorente, Cristina

PY - 2023/11/1

Y1 - 2023/11/1

N2 - B-cell acute lymphoblastic leukemia (B-ALL) is the most common subtype of acute leukemia in the pediatric population. The prognosis and treatment of B-ALL have dramatically improved over the past decade with the adoption of intensive and prolonged combination chemotherapy regimens. The advent of novel immunologic agents such as blinatumomab and inotuzumab has changed the treatment landscape of B-ALL. However, patients have continued to relapse, raising the need for novel therapies. Chimeric antigen receptor (CAR) T-cells have achieved a milestone in the treatment of B-ALL. Two CD19-targeting CAR T-cells were approved by the Food and Drug Administration and the European Medicines Agency for the treatment of relapsed and/or refractory B-ALL. In this review, we review the available data regarding CD19-targeting CAR T-cells with their safety profile as well as the mechanism of resistance to these agents and the way to overcome this resistance.

AB - B-cell acute lymphoblastic leukemia (B-ALL) is the most common subtype of acute leukemia in the pediatric population. The prognosis and treatment of B-ALL have dramatically improved over the past decade with the adoption of intensive and prolonged combination chemotherapy regimens. The advent of novel immunologic agents such as blinatumomab and inotuzumab has changed the treatment landscape of B-ALL. However, patients have continued to relapse, raising the need for novel therapies. Chimeric antigen receptor (CAR) T-cells have achieved a milestone in the treatment of B-ALL. Two CD19-targeting CAR T-cells were approved by the Food and Drug Administration and the European Medicines Agency for the treatment of relapsed and/or refractory B-ALL. In this review, we review the available data regarding CD19-targeting CAR T-cells with their safety profile as well as the mechanism of resistance to these agents and the way to overcome this resistance.

KW - B-cell acute lymphoblastic leukemia

KW - blinatumomab

KW - brexucabtagene autoleucel

KW - cytokine release syndrome

KW - immune effector cell-associated neurotoxicity syndrome

KW - tisagenlecleucel

UR - http://www.scopus.com/inward/record.url?scp=85176556569&partnerID=8YFLogxK

U2 - 10.3390/jcm12216883

DO - 10.3390/jcm12216883

M3 - Review article

AN - SCOPUS:85176556569

SN - 2077-0383

VL - 12

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

IS - 21

M1 - 6883

ER -